Congressional ‘Cures’ Debate Shifts To FDA Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
You may also be interested in...
US FDA Getting More Money Up Front Under Cures Bill Revisions
Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.
Off-Label Communication Growth: Could FDA Afford To Police It?
Another user fee for the US drug agency could help pay for research of off-label uses, but lack of resources could be a regulatory problem.
Senate's Medical Innovation Bill Takes Cures' Shape
HELP Committee chairman finally calls his package a companion to 21st Century Cures bill, but more work is necessary to bring it in line with the House legislation.